ArticleThe American journal of pathology2004
Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.
Article in The American journal of pathology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 79 citations in OpenAlex.
- Review
- Nanopore sensing of protein and peptide conformation for point-of-care applications.Nature communications · 2025Review
- Racemases and epimerases operating through a 1,1-proton transfer mechanism: reactivity, mechanism and inhibition.Chemical Society reviews · 2021Review
- High-Performance Near-Infrared Fluorescent Secondary Antibodies for Immunofluorescence.Analytical chemistry · 2021Article
- Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?Frontiers in oncology · 2021Review
- Article
- Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.Advanced drug delivery reviews · 2020Review
- Article
- A study on the AMACR catalysed elimination reaction and its application to inhibitor testing.Organic & biomolecular chemistry · 2016Article
- Targeting prostate cancer cell metabolism: impact of hexokinase and CPT-1 enzymes.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- The fat side of prostate cancer.Biochimica et biophysica acta · 2013Review
- Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.Molecular & cellular proteomics : MCP · 2013Article
- Urinary biomarkers for prostate cancer: a review.Asian journal of andrology · 2013Review
- High-throughput screen identifies novel inhibitors of cancer biomarker α-methylacyl coenzyme A racemase (AMACR/P504S).Molecular cancer therapeutics · 2011Article
- Cancer biomarker discovery: the entropic hallmark.PloS one · 2010Article
- Plasma phytanic acid concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition.The American journal of clinical nutrition · 2010Article
- Establishment and genomic characterization of mouse xenografts of human primary prostate tumors.The American journal of pathology · 2010Article
- New and novel markers for prostate cancer detection.Current urology reports · 2009Review
- Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.PLoS genetics · 2009Article
- A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.Cancer research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Alpha-methylacyl-CoA racemase (AMACR) is a peroxisomal and mitochondrial enzyme involved in the beta-oxidation of branched fatty acids, shown to be elevated in prostate cancer by several recent studies. Sequence variants of AMACR have been linked to prostate cancer risk. Although mRNA transcript, protein, and sequence variants of AMACR have been studied in the context of prostate cancer, AMACR enzymatic activity has not been addressed. Here we present evidence that AMACR activity is consistently elevated in prostate cancer tissue specimens. This activity can be immunodepleted from prostate cancer tissue extracts. Furthermore, mock needle biopsy cores containing foci of prostate cancer exhibited increased AMACR enzymatic activity, correlating with both protein levels and histopathology. Taken together, our studies suggest that AMACR activity is increased in prostate cancer relative to benign epithelia and suggests that monitoring AMACR activity levels in prostate needle biopsies may have clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.